---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-25-001260"
form_type: "8-K"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:48:00.717193+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Onconetix presents Proclarix data at EAU; 96% sensitivity, 22% biopsy avoidance in Danish cohort

## Summary
- Proclarix evaluated in 808 patients; in targeted subpopulation (n=371), negative test gave 5% csPCa probability vs 14% for %fPSA (p=0.028).
- Proclarix avoided 22% of biopsies while missing only 3 of 101 csPCa cases (2 GG2, 1 GG3).
- In extended population (n=654, PSA 2-20 ng/mL), sensitivity 96%, specificity significantly higher than %fPSA and ERSPC RC (p<0.001).
- Data presented March 23, 2025 at EAU congress in Madrid; study led by Ahmed H. Zedan, MD, PhD of Lillebaelt Hospital.

## SEC filing metadata
- accession: 0001013762-25-001260
- form_type: 8-K
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000101376225001260/0001013762-25-001260-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000101376225001260/ea0235277-8k_oncon.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-25-001260
- JSON: https://secwatch.observer/filing/0001013762-25-001260.json
- Plain text: https://secwatch.observer/filing/0001013762-25-001260.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.